AADI Quote, Financials, Valuation and Earnings

iBio has a net margin of -173.96% compared to Aadi Bioscience's net margin of -4444.57%. Aadi Bioscience's return on equity of -66.83% beat iBio's return on equity of -148.3%.

Aadi Bioscience has a consensus price target of $3.00, signalling downside risk potential of -6.54%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 46.94%. Given that iBio has higher upside potential than Aadi Bioscience, analysts believe iBio is more attractive than Aadi Bioscience.

Aadi Bioscience has a beta of 1.978, which suggesting that the stock is 97.79% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Aadi Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aadi Bioscience pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Aadi Bioscience quarterly revenues are $7.2M, which are larger than iBio quarterly revenues of $175K. Aadi Bioscience's net income of -$12.5M is lower than iBio's net income of -$4M. Notably, Aadi Bioscience's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aadi Bioscience is 3.46x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

Immuneering has a net margin of -173.96% compared to Aadi Bioscience's net margin of --. Aadi Bioscience's return on equity of -66.83% beat Immuneering's return on equity of --.

Aadi Bioscience has a consensus price target of $3.00, signalling downside risk potential of -6.54%. On the other hand Immuneering has an analysts' consensus of -- which suggests that it could grow by 432.9%. Given that Immuneering has higher upside potential than Aadi Bioscience, analysts believe Immuneering is more attractive than Aadi Bioscience.

Aadi Bioscience has a beta of 1.978, which suggesting that the stock is 97.79% more volatile than S&P 500. In comparison Immuneering has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aadi Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aadi Bioscience pays -- of its earnings as a dividend. Immuneering pays out -- of its earnings as a dividend.

Aadi Bioscience quarterly revenues are $7.2M, which are larger than Immuneering quarterly revenues of --. Aadi Bioscience's net income of -$12.5M is higher than Immuneering's net income of -$14.6M. Notably, Aadi Bioscience's price-to-earnings ratio is -- while Immuneering's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aadi Bioscience is 3.46x versus 217.13x for Immuneering. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -173.96% compared to Aadi Bioscience's net margin of -49.65%. Aadi Bioscience's return on equity of -66.83% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Aadi Bioscience has a consensus price target of $3.00, signalling downside risk potential of -6.54%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than Aadi Bioscience, analysts believe NovaBay Pharmaceuticals is more attractive than Aadi Bioscience.

Aadi Bioscience has a beta of 1.978, which suggesting that the stock is 97.79% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Aadi Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aadi Bioscience pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Aadi Bioscience quarterly revenues are $7.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Aadi Bioscience's net income of -$12.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Aadi Bioscience's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aadi Bioscience is 3.46x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -173.96% compared to Aadi Bioscience's net margin of -2357.27%. Aadi Bioscience's return on equity of -66.83% beat Palatin Technologies's return on equity of --.

Aadi Bioscience has a consensus price target of $3.00, signalling downside risk potential of -6.54%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Aadi Bioscience, analysts believe Palatin Technologies is more attractive than Aadi Bioscience.

Aadi Bioscience has a beta of 1.978, which suggesting that the stock is 97.79% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Aadi Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aadi Bioscience pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Aadi Bioscience quarterly revenues are $7.2M, which are larger than Palatin Technologies quarterly revenues of $350K. Aadi Bioscience's net income of -$12.5M is lower than Palatin Technologies's net income of -$7.8M. Notably, Aadi Bioscience's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aadi Bioscience is 3.46x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.